Paragon 28 Announces Acquisition of Disior
Paragon 28, Inc. (NYSE: FNA) has announced the acquisition of Disior Oy, a software company specializing in 3D analytics for foot and ankle surgery. The $18 million upfront payment, with potential future payments of up to $8 million, aims to enhance Paragon 28's SMART 28™ ecosystem. This integration will improve pre-operative planning and surgical outcomes for foot and ankle surgeons, aligning with Paragon 28's mission to modernize surgery and enhance patient care.
- Acquisition of Disior enhances SMART 28™ pre-operative planning capabilities.
- Potential future payments incentivize the achievement of technological advancements and milestones.
- Synergies with Additive Orthopaedics support market expansion.
- The $18 million upfront payment could strain short-term liquidity.
- Reliance on contingent payments for future growth may pose risks.
Disior advances Paragon 28’s SMART 28™ strategy, providing a comprehensive 3D analytics and pre-operative planning platform, and will immediately accelerate internal research programs
Disior will be an integral component to SMART 28™, the company’s ecosystem of enabling technologies for pre-operative planning, intra-operative support, and post-operative evaluation.
Disior’s anatomy-specific surgical modules will provide foot and ankle surgeons the objective data needed for the diagnosis and creation of patient-specific surgical plans, and assessment of patient outcomes. Disior is also highly complementary to the assets of Additive Orthopaedics, which P28 acquired in May of 2021.
"Disior advances our previously communicated growth strategy to target unique technologies and will immediately accelerate our internal research and development efforts, plus provide surgeons unique pre-operative planning capabilities. Disior’s software combined with our broad product portfolio further differentiates us from the competition," said
“The entire Disior team is very excited to join the
For additional information on SMART 28™ and Disior, a presentation is available on the Events and Presentation section of the Company’s investor relations website.
Transaction Details
Pursuant to the terms of the acquisition agreement,
About
Based in
Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to: Paragon 28’s potential to shape a better future for foot and ankle patients and Disior becoming an integral component to SMART 28™. You are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements are only predictions based on our current expectations, estimates, and assumptions, valid only as of the date they are made, and subject to risks and uncertainties, some of which we are not currently aware. Forward-looking statements should not be read as a guarantee of future performance or results and may not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. These forward-looking statements are based on Paragon 28’s current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. These risks and uncertainties are described more fully in the section titled “Risk Factors” in Paragon 28’s filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005421/en/
Investor Contact:
investors@neuropace.com
Source:
FAQ
What is the purpose of Paragon 28's acquisition of Disior?
How much did Paragon 28 pay for Disior?
What impact will Disior have on Paragon 28's operations?
When was the acquisition of Disior announced?